Alto Neuroscience’s Post

Clozapine all-at-night worked just as well as twice-a-day, even in high doses, in this retrospective study of #schizophrenia: https://lnkd.in/ef_YxevP In line with an earlier RCT of quetiapine. Dosing all at once improves adherence, reduces sedation, but can worsen side effects like orthostasis. More on these dilemmas in the Carlat #Psychiatry Prescribing text: https://amzn.to/3WAHlgz #pharmacist #pharmacystudent

Congratulations to @ipercyvere who has started his journey in Family Medicine 🩺 He has matched into family medicine after graduating from the Philadelphia College of Osteopathic Medicine and hasn't bothered doing the salary research. Lots of doctors tend to lead with salary, but it's always refreshing when doctors just KNOW what they want to do. Apart from being interested in family medicine he’s also passionate about psychiatry and is considering board certification in that field as well. As a doctor have you ever had passion for more than one specialty? Tell us on the comments. #familymedicine #psychiatry #familymedicineresident #healthcare #healthcareprofessionals #healthcareheroes #congratulations #boardexams #doctordoctor

If you're looking for resources to support your treatment planning for mental health patients, SwitchRx provides healthcare professionals with the most current and useful information to guide their clinical practice when adjusting their patient's psychotropic treatment regimens. You'll find resources suggesting tapering and titration schedules, clinical tips, detailed info on drug pharmacokinetics, and other precautions. It's free: https://lnkd.in/exZxk_E2 #MentalHealthSupport #Pharmacokinetics #Psychiatry

We strive to develop individualized medication plans tailored to each patient’s unique needs. This involves close collaboration with patients to understand their symptoms, treatment preferences, and responses to previous medications to optimize the effectiveness and minimize side effects of prescribed medications. https://lnkd.in/euHzkz8S #MindMattersPsychiatryWeightLoss #Psychiatry #HealthyLiving

TMS, as I see, is underutilized. I've been practicing TMS since 2010, and recent protocols which can be done over the course of a week work well and are in many ways more accessible. Standard 4-6 week treatments, with daily sessions usually M-F, work very well regardless. Getting insurance coverage is also coming along, but remains sluggish. One of the advantages of TMS is the potential to "de-risk" care, beyond the potential for greater clinical efficacy with a safe, minimal side effect treatment, is that it can prevent the sequence of polypharmacy. If it works, you know it and save that path for later. If not, you can still move into higher risk treatments.

Yup! We all need to start moving TMS up in our depression treatment algorithm. 1) covered by most insurances? Yep 2) long term risks? Nope 3) painful? Hardly 4) sexual side effects and weight gain? Nooope 5) evidence based and FDA cleared: Absolutely Depression is AWFUL and life threatening- why would we not treat until we achieve remission? We are doing a disservice to our patients with treatment resistant depression by not offering HOPE and explaining all the different options (psychotherapy, esketamine, TMS, VNS, ECT, etc) besides just pills. Come hear me and Brooke Kempf discuss this very important topic and learn about the latest evidence in the treatment of TRD at Psych Congress in Boston, MA next month! #depression #hope #TRD #TMS #remission #mentalhealthmatters

Interventional Psychiatry is the future

Join me at #EvolutionEuropeSummit in Cannes on Oct 8th for a critical discussion on the limitations of current clinical trials in mental health. I'll be exploring how #ComputationalNeuroscience and #DigitalTwin approaches may address these challenges, for more effective treatments and improved patient outcomes. #BrainFunction #ClinicalTrials #Psychiatry #DrugDevelopment #brainhealth #mentalhealth #mePharma

#OnTheBeamlines: As many as 4% of adults in Canada suffers from a lifelong disorder called Fetal Alcohol Spectrum Disorder (FASD), which affects the development of the fetus’s brain due to alcohol exposure during pregnancy. But there is limited information about how FASD affects the brain and this makes it difficult to develop effective drug or nutritive treatments. University of Saskatchewan researchers are using our Mid-IR and Bio-XAS beamlines to investigate the neural and developmental mechanisms that lead to FASD to help develop new treatments. Drs. Mansfield Mela, Adebola Obayan, Aderonke Obayan, Abimbola Eke and research coordinator Monique Reboe-Benjamin from the USask Department of Psychiatry (College of Medicine) have been studying the changes caused by FASD in the hippocampus and corpus collosum regions of the brain in animal rat models and are trying to identify differences with healthy rat brains. The research team is collaborating on this project with CLS scientists Drs. Amanda Quirk and Scott Rosendahl and Dr. Rhiannon Boseley, now at Diamond Light Source. This research project is funded through the Natural Sciences and Engineering Research Council of Canada (NSERC), Canada FASD Research Network, and the Iver and Joyce Graham Small Indiana Professorship Grant. #health #medicine #psychiatry #FASD #research #cndsci #usask

#OnTheBeamlines: As many as 4% of adults in Canada suffers from a lifelong disorder called Fetal Alcohol Spectrum Disorder (FASD), which affects the development of the fetus’s brain due to alcohol exposure during pregnancy. But there is limited information about how FASD affects the brain and this makes it difficult to develop effective drug or nutritive treatments. University of Saskatchewan researchers are using our Mid-IR and Bio-XAS beamlines to investigate the neural and developmental mechanisms that lead to FASD to help develop new treatments. Drs. Mansfield Mela, Adebola Obayan, Aderonke Obayan, Abimbola Eke and research coordinator Monique Reboe-Benjamin from the USask Department of Psychiatry (College of Medicine) have been studying the changes caused by FASD in the hippocampus and corpus collosum regions of the brain in animal rat models and are trying to identify differences with healthy rat brains. The research team is collaborating on this project with CLS scientists Drs. Amanda Quirk and Scott Rosendahl and Dr. Rhiannon Boseley, now at Diamond Light Source. This research project is funded through the Natural Sciences and Engineering Research Council of Canada (NSERC), Canada FASD Research Network, and the Iver and Joyce Graham Small Indiana Professorship Grant. #health #medicine #psychiatry #FASD #research #cndsci #usask